CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Scancell Holdings plc

SCLP.L
$168MMicro Cap

Next catalyst

Phase 2January 2027

SCIB1 or iSCIB1+ DNA vaccine

Malignant Melanoma

Get an email about SCLP.L's next catalysts

Track Scancell Holdings (SCLP.L) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

SCIB1 or iSCIB1+ DNA vaccine Phase 2 Est. Readout

January 2027~SCIB1 or iSCIB1+ DNA vaccine173

Estimated primary completion for SCIB1 or iSCIB1+ DNA vaccine trial (NCT04079166) in Malignant Melanoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

AIMPharmaceutical Preparations🇬🇧EuropeOxford60 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Scancell Holdings plc's drug pipeline?→

CatalystAlert tracks 2 drug candidates in Scancell Holdings plc's (SCLP.L) pipeline across Phase 2. Its lead program is SCIB1 or iSCIB1+ DNA vaccine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Scancell Holdings plc's next FDA catalyst?→

Scancell Holdings plc's (SCLP.L) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track SCLP.L biotech catalysts?→

Add SCLP.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scancell Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply